However, the same level of intracranial activity was not observed in the context of primary brain tumors: depatuxizumab mafodotin (Depatux-M), despite its promises, has failed to demonstrate efficacy in patients with EGFR-amplified GBM in both the adjuvant and recurrent treatment settings. Here, EGFR is linked to glioblastoma.